ARDX Insider Trading

Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $4,316,176.94
Insider Selling (Last 12 Months): $5,578,531.89

Ardelyx Insider Trading History Chart

This chart shows the insider buying and selling history at Ardelyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$1.94Mbought$709ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Ardelyx Share Price & Price History

Current Price: $4.02
Price Change: Price Increase of +0.045 (1.13%)
As of 05/27/2025 01:52 PM ET

This chart shows the closing price history over time for ARDX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JulAugSepOctNovDecJanFebMarAprMay$3.97Closing price on 05/26/25:

SEC Filings (Institutional Ownership Changes) for Ardelyx (NASDAQ:ARDX)

58.92% of Ardelyx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARDX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$52Mbought$4.16MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More on Ardelyx

Today's Range

Now: $4.02
Low: $3.98
High: $4.06

50 Day Range

MA: $4.50
Low: $3.28
High: $5.51

52 Week Range

Now: $4.02
Low: $3.21
High: $8.06

Volume

1,200,972 shs

Average Volume

4,442,502 shs

Market Capitalization

$960.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Who are the company insiders with the largest holdings of Ardelyx?

Ardelyx's top insider investors include:
  1. David M Mott (Director)
  2. Michael Raab (CEO)
  3. Justin A Renz (CFO)
  4. Laura A Williams (Insider)
  5. David P Rosenbaum (Insider)
  6. Robert Blanks (Insider)
  7. Susan Rodriguez (Insider)
  8. Eric Duane Foster (Insider)
  9. Elizabeth A Grammer (Insider)
  10. Mike Kelliher (Insider)
  11. Robert Ora Felsch (Insider)
Learn More about top insider investors at Ardelyx.

Who are the major institutional investors of Ardelyx?

Ardelyx's top institutional investors include:
  1. Vanguard Group Inc. — 6.27%
  2. Millennium Management LLC — 2.70%
  3. Nuveen LLC — 1.42%
  4. Goldman Sachs Group Inc. — 0.99%
  5. Northern Trust Corp — 0.91%
  6. Two Seas Capital LP — 0.89%
Learn More about top institutional investors of Ardelyx stock.

Which major investors are selling Ardelyx stock?

During the previous quarter, ARDX stock was sold by these institutional investors:
  1. Hsbc Holdings PLC
  2. Rafferty Asset Management LLC
  3. Knott David M Jr
  4. Capital Fund Management S.A.
  5. Pekin Hardy Strauss Inc.
  6. Algert Global LLC
  7. XTX Topco Ltd
  8. Simplex Trading LLC
In the last year, company insiders that have sold Ardelyx company stock include:
  1. David M Mott (Director)
  2. Michael Raab (CEO)
  3. Justin A Renz (CFO)
  4. Laura A Williams (Insider)
  5. David P Rosenbaum (Insider)
  6. Robert Blanks (Insider)
  7. Susan Rodriguez (Insider)
  8. Eric Duane Foster (Insider)
Learn More investors selling Ardelyx stock.

Which major investors are buying Ardelyx stock?

Within the previous quarter, ARDX stock was acquired by institutional investors including:
  1. Millennium Management LLC
  2. Nuveen LLC
  3. AQR Capital Management LLC
  4. Trexquant Investment LP
  5. Vanguard Group Inc.
  6. Adage Capital Partners GP L.L.C.
  7. ADAR1 Capital Management LLC
  8. Universal Beteiligungs und Servicegesellschaft mbH